Next Article in Journal
Co-Improvement in Electrocatalytic Hydrogen Evolution Performance of MoS2 by Ni Doping and Graphene Oxide Compounding
Previous Article in Journal
Ultrasound-Assisted Extraction of Polysaccharides from Lyophyllum decastes: Structural Analysis and Bioactivity Assessment
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Advanced Nanomedicine Delivery Systems for Cardiovascular Diseases: Viral and Non-Viral Strategies in Targeted Therapy

Shanghai Frontiers Science Research Center for Druggability of Cardiovascular Noncoding RNA, Institute for Frontier Medical Technology, College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai 201620, China
*
Authors to whom correspondence should be addressed.
Molecules 2025, 30(4), 962; https://doi.org/10.3390/molecules30040962
Submission received: 9 January 2025 / Revised: 8 February 2025 / Accepted: 13 February 2025 / Published: 19 February 2025

Abstract

Cardiovascular diseases (CVDs) represent a leading global health crisis, significantly impairing patients’ quality of life and posing substantial risks to their survival. Conventional therapies for CVDs often grapple with challenges such as inadequate targeting precision, suboptimal therapeutic efficacy, and potential adverse side effects. To address these shortcomings, researchers are intensively developing advanced drug delivery systems characterized by high specificity and selectivity, excellent biodegradability, superior biocompatibility, and minimal toxicity. These innovative systems enable the precise delivery of pharmaceuticals with high drug-loading capacities, minimal leakage, and expansive specific surface areas, thereby enhancing therapeutic outcomes. In this review, we summarize and classify various drug delivery materials targeting CVDs and application values. We also evaluate the feasibility and efficacy of viral and non-viral vectors for the treatment of CVDs, the existing limitations and application prospects are also discussed. We hope that this review will provide new perspectives for the future development of drug delivery systems for the treatment of CVDs, ultimately contributing to improved patient care and outcomes.
Keywords: cardiovascular disease; nanomedicine delivery system; viral vectors; non-viral vectors; targeted therapy cardiovascular disease; nanomedicine delivery system; viral vectors; non-viral vectors; targeted therapy

Share and Cite

MDPI and ACS Style

Chen, Q.; Yu, T.; Gong, J.; Shan, H. Advanced Nanomedicine Delivery Systems for Cardiovascular Diseases: Viral and Non-Viral Strategies in Targeted Therapy. Molecules 2025, 30, 962. https://doi.org/10.3390/molecules30040962

AMA Style

Chen Q, Yu T, Gong J, Shan H. Advanced Nanomedicine Delivery Systems for Cardiovascular Diseases: Viral and Non-Viral Strategies in Targeted Therapy. Molecules. 2025; 30(4):962. https://doi.org/10.3390/molecules30040962

Chicago/Turabian Style

Chen, Qian, Tong Yu, Jingyi Gong, and Hongli Shan. 2025. "Advanced Nanomedicine Delivery Systems for Cardiovascular Diseases: Viral and Non-Viral Strategies in Targeted Therapy" Molecules 30, no. 4: 962. https://doi.org/10.3390/molecules30040962

APA Style

Chen, Q., Yu, T., Gong, J., & Shan, H. (2025). Advanced Nanomedicine Delivery Systems for Cardiovascular Diseases: Viral and Non-Viral Strategies in Targeted Therapy. Molecules, 30(4), 962. https://doi.org/10.3390/molecules30040962

Article Metrics

Back to TopTop